Biogen (BIIB) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biogen (BIIB) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 45.9% versus a gain of 4.7%. Over five years, NBIX leads with a +37.2% price change compared with -21.0% for BIIB. Biogen is the larger company by market cap ($32.06 billion vs $14.33 billion), about 2.2 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +2.2%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 13.1x for Biogen). Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | NBIX |
|---|---|---|
| Share price | $217.00 | $140.96 |
| Market cap | $32.06B | $14.33B |
| 1-day change | -2.32% | -1.75% |
| YTD return | +26.23% | +1.16% |
| 1-year return | +45.95% | +4.72% |
| 5-year return | -21.00% | +37.24% |
| P/E ratio (TTM) | 38.54 | 20.67 |
| Forward P/E | 13.14 | 11.87 |
| EPS (TTM) | $5.63 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $2.86B |
| Revenue growth (YoY) | +2.22% | +21.45% |
| Net income (latest FY) | $1.29B | $478.60M |
| Gross margin | 75.69% | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | 13.07% | 16.73% |
| 52-week high | $230.49 | $186.12 |
| 52-week low | $138.00 | $122.14 |
| Distance from 52-week high | -5.85% | -24.26% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +9.76% | +47.06% |
| Average volume | 1.07M | 1.30M |
| Shares outstanding | 147.75M | 101.65M |
| Employees | 7,500 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 2.2 times larger than Neurocrine Biosciences by market value ($32.06B vs $14.33B).
- BIIB has outperformed NBIX by 41.2 percentage points over the past year.
- Biogen trades at a higher earnings multiple (38.5x vs 20.7x trailing P/E).
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +2.22%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
BIIB vs NBIX FAQ
Which is bigger, Biogen or Neurocrine Biosciences?
Biogen (BIIB) is larger, with a market capitalization of $32.06B compared with $14.33B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, BIIB or NBIX?
BIIB returned +45.95% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or NBIX?
NBIX has the lower trailing P/E at 20.7, versus 38.5 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biogen and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.